Back to top

Analyst Blog

Repros Therapeutics Inc. (RPRX - Snapshot Report) recently announced that two additional patents covering its candidate, Androxal, have been issued. Both patents (8,372,887 and 8,377,991) related to metabolic consequences of low testosterone and the favorable effect of restoring testicular functions by Androxal are valid till 2028 and 2031, respectively.

The 991’ patent covering the treatment of type II diabetes was issued on the basis of data from the phase II study (ZA-202). The study evaluated the use of Androxal for improvement of glycemic control in males suffering from type II diabetes, who are being treated with oral hypoglycemic agents for their condition. The results from the study were encouraging.

Repros is also developing Androxal for other indications including secondary hypogonadism. Last month Repros provided encouraging top-line results from the ZA-301 study on Androxal for the treatment of secondary hypogonadism.

The results showed that 79% of the patients had 24-hour average total testosterone in a normal range at the end of 12 weeks of treatment with the drug. Completer – a separate analysis – showed 83% of men were within the normal testosterone range.

Moreover, the drug’s impact on sperm concentration also met the threshold criteria of the US Food and Drug Administration (FDA) as Androxal exhibited non-inferiority to placebo at a margin of 20%. Repros reported that Androxal was generally well-tolerated in the study with no adverse events leading to discontinuation in the Androxal arm.

Repros currently carries a Zacks Rank #4 (Sell). Currently, companies like Transcept Pharmaceuticals, Inc. , Cleveland BioLabs, Inc. and QLT Inc. (QLTI - Analyst Report) look more attractive with a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
SYNAPTICS I… SYNA 78.11 +8.14%
CENTURY ALU… CENX 19.88 +5.74%
GREEN PLAIN… GPRE 39.41 +5.12%
PILGRIM'S P… PPC 28.82 +3.08%
THE PANTRY… PTRY 18.41 +2.79%